Methiopropamine
Viewing r1.a1 — Oct 2, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
MPA (methiopropamine) is a synthetic stimulant of the thiophene class. It is the direct thiophene structural analog of methamphetamine, roughly five times less potent.[1] It blocks dopamine and norepinephrine reuptake in the brain, producing wakefulness, focus, and mild stimulation.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
MPA was first synthesized in 1942 as part of a program modifying amphetamine's ring structure.[2] It showed no clinical promise and lay dormant until 2010, when it appeared on the UK "legal high" market as "Synthacaine," sold as a cocaine substitute.[3] It is now controlled in the US, UK, Germany, and China, with the WHO recommending international scheduling.[4]
Subjective effects include enhanced wakefulness, sustained attention, mood elevation, appetite suppression, and mild physical energy. The experience is functional rather than euphoric — steady and focus-oriented, closer to methylphenidate than to amphetamine, without the hedonic rush or social warmth of more potent stimulants.[3] Fatigue, irritability, and low mood on the comedown are common, and compulsive redosing is one of MPA's most consistently reported features.
MPA carries significant dependence potential — structural brain rewiring appears after as few as four doses in animals[5] — and chronic exposure caused heart damage and sudden death in mice without prior warning signs.[6] The dose-response curve is steep: effects escalate sharply within a narrow range, and no lethal dose has been established in any species. No controlled human studies exist; current understanding rests on rodent research, clinical case reports, and forensic data.
History[edit]
History
Synthesis and Early Obscurity
MPA was first synthesized in 1942 by Frederick F. Blicke and John H. Burckhalter, as part of a program replacing amphetamine's benzene ring with heterocyclic alternatives.[2] It showed lower stimulant potency than methamphetamine and offered no clinical advantage. It was forgotten for nearly seven decades.
Emergence on the NPS Market
MPA resurfaced in December 2010 on the UK "legal high" market, sold under names including "Blow," "Synthacaine," and "Bomb."[3] "Synthacaine" — the most widely distributed product — contained MPA mixed with 2-aminoindane, marketed explicitly as a cocaine substitute.[7] Clinical detection followed in 2011,[8] and by 2012 MPA was confirmed in pooled urine samples from London public urinals.[9]
Regulatory Response
The UK banned MPA in November 2015 under a Temporary Class Drug Order, with permanent Class B status taking effect in November 2017.[3] The United States placed MPA in Schedule I in December 2022.[10] The WHO subsequently recommended international Schedule II placement.[4]
The name "methiopropamine" derives from the compound's structural identity: "methio-" for the thiophene ring that replaces methamphetamine's benzene, and "-propamine" for the propylamine side chain shared with its parent compound. On the NPS market, MPA was rarely sold under its chemical name — branded products like "Synthacaine" positioned it as a legal cocaine alternative, a framing that shaped both its user base and its regulatory trajectory. The first published case of acute intoxication, in 2016, involved a patient who consumed "Synthacaine" and presented with paranoid delusions and hallucinations.[11]
Chemistry[edit]
Chemistry
MPA belongs to the thiophene class of substituted amphetamines — it is methamphetamine with its benzene ring replaced by a five-membered, sulfur-containing thiophene ring. This structural swap preserves the molecule's overall shape while altering its electronic properties and metabolic behavior. Its molecular formula is C₈H₁₃NS (molecular weight 155.26 g/mol as the free base).
MPA has a chirality center, giving rise to two mirror-image molecular forms. All preparations and seized samples analyzed to date are racemic mixtures — equal parts of both forms.[12] By analogy with methamphetamine — where one form is substantially more potent — differential activity between MPA's forms is plausible but has never been tested.[12]
Pharmacology[edit]
Pharmacology
Mechanism of Action
MPA is a norepinephrine-dopamine reuptake inhibitor. It blocks the transporters that clear dopamine and norepinephrine from the synapse, raising their levels in the brain's reward and arousal circuits.[1] This makes it mechanistically closer to methylphenidate than to amphetamine — both block reuptake, while amphetamine actively releases stored dopamine, which explains amphetamine's greater intensity.[1][13]
MPA is roughly five times less potent than methamphetamine in animal studies,[1] and about one-fifth as potent as dextroamphetamine at the DAT.[12] Serotonin transporter inhibition is negligible at typical doses — roughly 50 times higher concentrations are required.[1]
Pharmacokinetics
No controlled human pharmacokinetic studies exist. MPA is metabolized via N-demethylation and aromatic hydroxylation.[14] The specific liver enzymes are unconfirmed; CYP2D6 involvement is inferred from structural similarity to methamphetamine.[14] inferred Bioavailability, half-life, and volume of distribution in humans are entirely unknown.
Neuroscience[edit]
Neuroscience
Where It Acts
MPA raises catecholamine levels in the nucleus accumbens and prefrontal cortex — the brain regions that underlie reward, motivation, and sustained attention. This produces reinforcement, mild euphoria, wakefulness, and the focused arousal that defines MPA's functional character.
Repeated exposure structurally rewires the nucleus accumbens: after as few as four doses in rats, dendritic spine density increased — a pattern shared with amphetamine and cocaine, reflecting the brain progressively wiring in drug-seeking behavior.[5]
Repeated MPA exposure in mice triggers oxidative stress, brain immune activation, and reduced dopamine system markers — a neurotoxicity pattern similar to methamphetamine, though requiring higher doses.[16] Seven-day exposure impaired working and recognition memory, with deficits persisting at least 24 hours after the last dose.[17] Whether these effects occur at recreational doses in humans, and whether they persist, remains unknown. Whether MPA's two molecular forms differ in potency — as methamphetamine's do — has also never been tested.
Subjective Effects[edit]
Subjective Effects
MPA produces a functional, task-oriented stimulation. The experience is defined by sharpened focus and sustained wakefulness rather than euphoria — steady and purposeful rather than recreational. At higher doses the heart races, the jaw tightens, and appetite disappears, but the core character remains more driven than hedonic.
Among stimulants, MPA sits closest to methylphenidate — users consistently describe a "functional" rather than recreational quality at typical doses.[3] It lacks the serotonergic warmth of MDMA and the dopaminergic punch of amphetamine, sitting in a quieter register than either.
Effect Grid
Clear stimulant effects establish themselves: sustained wakefulness, focus enhancement, and mild cognitive euphoria. Thought acceleration and thought organization improve task engagement. Analysis enhancement is noticeable. Motivation enhancement supports sustained productivity. Music enhancement may be subtly present.
Appetite suppression is moderate and reliable. Stimulation is clearly perceptible — increased energy and physical alertness without the intensity of amphetamine. Heart rate elevation is common. Spontaneous body sensations and mild temperature dysregulation may emerge. Bruxism and excessive sweating are possible but typically mild.
Compulsive redosing urge may emerge at this tier — users frequently describe wanting to sustain the functional stimulation. Oral duration is 6–10 hours. Insomnia is likely if taken in the afternoon or evening. Comedown involves mild fatigue, irritability, and low mood.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual processing acceleration · Visual acuity enhancement · Auditory hallucinations · External hallucinations · Shadow people
Shadow people
Dry mouth · Insomnia · Pupil dilation · Dehydration sensation · Heart rate perception changes · Physical fatigue · Restlessness · Excessive sweating · Body high · Muscle tension · Respiratory stimulation · Sexual arousal enhancement · Spontaneous body sensations · Bruxism · Bodily lightness · Headache · Nausea · Tingling / electric sensations · Trembling · Motor control enhancement · Constipation · Dizziness · Nasal congestion · Tactile euphoria · Abnormal heartbeat · Pain suppression · Vibrations / buzzing · Vomiting · Tactile hallucination
Dehydration sensation · Heart rate perception changes · Physical fatigue · Restlessness · Excessive sweating · Body high · Muscle tension · Respiratory stimulation · Sexual arousal enhancement · Spontaneous body sensations · Bruxism · Bodily lightness · Headache · Nausea · Tingling / electric sensations · Trembling · Motor control enhancement · Constipation · Dizziness · Nasal congestion · Tactile euphoria · Pain suppression · Vibrations / buzzing · Vomiting · Tactile hallucination
Immersion enhancement · Pattern recognition enhancement · Focus enhancement · Analysis enhancement · Motivation enhancement · Information processing enhancement · Thought organization · Aesthetic enhancement · Cognitive dysphoria · Cognitive flexibility · Language enhancement · Novelty enhancement · Thought connectivity · Creativity enhancement · Humor enhancement · Memory enhancement · Motivation suppression · Cognitive impairment · Conceptual thinking · Confusion · Creativity suppression · Multiple thought streams · Suggestibility suppression · Thought deceleration · Thought disorganization · Thought loops
Motivation enhancement · Information processing enhancement · Thought organization · Aesthetic enhancement · Cognitive dysphoria · Cognitive flexibility · Language enhancement · Novelty enhancement · Thought connectivity · Creativity enhancement · Humor enhancement · Memory enhancement · Motivation suppression · Cognitive impairment · Conceptual thinking · Confusion · Creativity suppression · Multiple thought streams · Suggestibility suppression · Thought deceleration · Thought disorganization · Thought loops
Anhedonia · Emotional enhancement · Dysphoria · Emotional lability · Mania
Emotional lability
Ego inflation · Sociability enhancement · Flow state · Automaticity · Social connection · Self-control enhancement
Social connection · Self-control enhancement
Timeline
Gradual awareness of mild stimulation. Slight increase in alertness and wakefulness without clear euphoria.
Building wakefulness and focus. Mild body stimulation emerges. Appetite suppression begins.
Full stimulant effect — sustained attention, wakefulness, appetite suppression, mild cognitive euphoria. Task engagement enhanced. Compulsive redosing urge may emerge.
Stimulation sustains at reduced intensity. Focus persists but euphoria fades. Restlessness may replace productive engagement.
Gradual diminishment of stimulation. Emerging fatigue and irritability. Appetite begins to return.
Residual wakefulness, low mood, tiredness, possible headache. Cognitive fatigue and motivation suppression may persist.
⚠ Avoid driving during afterglow — residual cognitive fatigue and irritability may impair reaction time.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- High
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- amphetamine · methamphetamine · methylphenidate
Toxicity
Acute Toxicity
No lethal dose has been established for MPA in any species, and no controlled human toxicity data exist. Effects escalate sharply within a narrow dose range in rodents[1] — the gap between mild stimulation and dangerous cardiovascular strain is narrower than for most stimulants.
At lower doses close to typical human use, no hazardous effects were observed in mice, while higher doses produced rapid heart rate, elevated blood pressure, low oxygen saturation, and motor stereotypies.[13] This deceptive "gray zone" may encourage dose escalation.[13]
Cardiovascular Toxicity
Chronic MPA exposure in mice caused heart muscle damage, kidney and gut tissue death, and — most critically — sudden death in 40% of treated animals, without prior warning signs in body weight, food intake, or coordination.[6]
In hospitalized human cases, rapid heart rate was the most common finding, appearing in 91% of 11 confirmed cases.[8] Elevated creatine kinase — a marker of muscle breakdown — appeared in 64% of hospitalized patients, though most cases involved multiple substances.[8]
Injection-Related Harm
Intravenous MPA use has been documented in Scotland, where it was linked to Staphylococcus aureus blood infections, heart valve infections, and septic emboli in prisoners.[18]
Post-Mortem Data
MPA was detected in one polydrug fatality at approximately 2.2 µg/L in femoral blood. Death was attributed to positional asphyxia during co-intoxication with designer benzodiazepines and stimulants; MPA's specific contribution remains unclear.[19]
Psychological Risks
High doses can produce paranoia, confusion, agitation, and hallucinations — documented in 64%, 64%, and 45% of hospitalized patients respectively.[8] One case involved paranoid delusions, auditory and visual hallucinations, and incoherent speech after consuming "Synthacaine."[11] One patient required transfer to inpatient psychiatric care.[8]
Seven days of repeated MPA exposure in mice impaired recognition memory, working memory, and reference memory — deficits persisting at least 24 hours after the last dose.[17] Low-normal doses also produced aggressive behavior that intensified with repeated exposure.[20]
Tolerance and Dependence
Tolerance develops with repeated use. Community estimates suggest a tolerance half-life of approximately 5 days, though no published study confirms this. safety citation needed Cross-tolerance with dopamine-active stimulants like amphetamine and methylphenidate is expected but untested.
Dependence liability is supported by multiple lines of animal evidence: locomotor sensitization after as few as four doses,[15] structural rewiring in the brain's reward center after four injections,[5] cognitive impairment persisting after cessation,[17] and frequent user reports of compulsive redosing. The WHO concluded MPA has abuse potential comparable to Schedule II substances.[4]
No physical withdrawal has been described. Psychological withdrawal — fatigue, low mood, irritability — is reported by users but has not been systematically studied.
Drug Interactions
Serotonergic Combinations
MPA's serotonin activity is negligible at typical doses.[1] Combining it with potent serotonergic agents creates additive risk. Combining MPA with MDAI or 5-IAI may trigger serotonin syndrome — dangerously high body temperature, elevated blood pressure, dilated pupils, and muscle breakdown that can lead to fatal kidney failure.[3] safety citation needed
MDMA co-administration is classified as dangerous. MDMA's potent serotonin release combined with MPA's catecholamine reuptake inhibitor creates credible serotonin toxicity risk and additive cardiovascular strain. safety citation needed
Tramadol
The MPA + tramadol combination carries lethal risk. Tramadol inhibits serotonin reuptake; combined with MPA's catecholamine blockade, this could precipitate serotonin syndrome and additive cardiovascular strain. No specific case report confirms this interaction, but the pharmacological basis is strong. safety citation needed
Alcohol
No published data exist on MPA + alcohol interaction. As with other stimulants, MPA may mask alcohol's sedative effects, leading to increased consumption and additive cardiovascular stress.
CYP-Mediated Interactions
MPA is metabolized by CYP liver enzymes.[14] If CYP2D6 is the primary enzyme — inferred but unconfirmed — drugs that inhibit CYP2D6, including fluoxetine, paroxetine, and bupropion, could raise MPA blood levels. Genetic CYP2D6 poor metabolizer status produces similar effects. inferred
Contraindications
No substance-specific contraindication studies exist. The following are inferred from MPA's pharmacological profile and documented toxicity:
Absolute contraindications:
- Pre-existing heart conditions (coronary artery disease, cardiomyopathy, arrhythmias, uncontrolled high blood pressure): MPA produces rapid heart rate in 91% of hospitalized cases[8] and heart muscle damage in chronic animal models.[6]
- Concurrent MAOI use: monoamine oxidase inhibitors combined with a catecholamine reuptake inhibitor risk a dangerous spike in blood pressure. inferred
Relative contraindications:
- Seizure disorders: stimulants as a class lower seizure threshold. inferred
- Psychotic disorders or bipolar disorder: acute psychosis, paranoid delusions, and hallucinations are documented in MPA intoxication.[8][11]
- Kidney impairment: muscle breakdown (elevated CK in 64% of hospitalized cases) and kidney tissue death in chronic animal models.[8][6]
- Pregnancy and lactation: no reproductive toxicity data exist; catecholaminergic stimulants are generally contraindicated due to vasoconstriction and developmental risks. inferred
- Concurrent serotonergic medication (SSRIs, SNRIs, MAOIs, tramadol): serotonin toxicity risk, particularly at higher doses.
Harm Reduction[edit]
Forms & Identification
MPA typically circulates as a white to off-white powder, though yellowish batches with a faint aniseed-like odor have been documented.[3] It has a history of being sold in branded products — most notably "Synthacaine" — that frequently contain other active substances, including 2-aminoindane.[7]
Reagent testing confirms chemical identity but cannot verify purity or detect all adulterants. A positive test confirms what is present, not what else might be.
Guidelines
- Test every batch. Branded NPS products have repeatedly contained substances other than what is advertised. Reagent testing is a minimum; quantitative analysis (e.g. FTIR or lab testing services) provides more reliable identification.
- Start low. The steep dose-response curve means the gap between a mild experience and a dangerous one is narrower than for most stimulants. Titrate upward slowly, particularly with a new batch.
- Avoid redosing. Compulsive redosing is one of MPA's most consistently reported features. Set a dose limit before the session and use a timer to enforce spacing.
- Stay hydrated and eat. Stimulant appetite suppression and fluid neglect compound cardiovascular strain. Drink water regularly and eat a meal before dosing.
- Avoid injection. Intravenous MPA use carries documented risks of serious bacterial infections including heart valve infections.[18]
Set & Setting
MPA's functional, low-euphoria character makes acute psychological crises less likely than with more potent stimulants, but agitation, paranoia, and hallucinations are documented at higher doses.[8] A calm, familiar environment with trusted company reduces the likelihood of anxiety escalation.
Plan sleep well in advance — the stimulant tail makes sleep difficult if dosing occurs in the afternoon or evening.
Aftercare & integration. MPA's comedown typically involves fatigue, low mood, and irritability. Prioritize sleep — a full night is the single most effective recovery measure. Eat nutrient-dense food, particularly protein and complex carbohydrates, to support neurotransmitter replenishment.
Avoid caffeine or other stimulants during the comedown — they extend cardiovascular strain without meaningfully improving mood.
If low mood or irritability persists beyond 48–72 hours, or if cravings to redose are strong, this signals that use patterns may be escalating. Track frequency and dose over time; the animal evidence for rapid dependence development[5] suggests motivational patterns can establish faster than subjective experience indicates.
Recovery & Support
MPA has no characterized physical withdrawal, but psychological dependence — driven by compulsive redosing and the motivational rewiring documented in animal models — can be difficult to interrupt without support. If use has become regular or difficult to stop, professional support from an addiction counselor or substance use service is appropriate.
SMART Recovery and similar evidence-based programs offer structured frameworks for stimulant dependence. In the UK, FRANK (0300 123 6600) and in the US, SAMHSA's National Helpline (1-800-662-4357) provide confidential guidance and referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
Uncomfortable but manageable: jitteriness, mild anxiety, elevated heart rate, jaw tension. These are unpleasant but not dangerous at typical doses.
Seek immediate help if: chest pain, seizure, loss of consciousness, extremely rapid or irregular heartbeat, confusion with paranoid delusions or hallucinations, body temperature hot to the touch through clothing, or signs of muscle breakdown (dark urine, severe muscle pain).
Immediate steps:
- 1. Call emergency services.
- 2. Move the person to a cool, quiet area. Remove excess clothing if overheating.
- 3. Do not restrain unless there is immediate danger of self-harm.
- 4. If unconscious but breathing, place in the recovery position.
- 5. Do not induce vomiting.
What to tell the dispatcher:
Provide the substance name (methiopropamine / MPA), estimated amount consumed, time of ingestion, route of administration, and current symptoms. Good Samaritan laws in many jurisdictions protect callers who seek help for drug-related emergencies.
Legal Status[edit]
Legal Status
MPA has been progressively controlled across major jurisdictions since its emergence on the NPS market, with the WHO recommending international Schedule II placement.[4]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Federally scheduled effective December 2022. Previously controlled in Florida (Schedule I, December 2012) and Arizona ("dangerous drug," April 2014)[10][21] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Temporary Class Drug Order effective 27 Nov 2015; permanent Class B under Amendment (No.2) Order 2017, effective 27 Nov 2017. Also covered by Psychoactive Substances Act 2016[3] |
| Germany | Anlage I (BtMG) | Controlled since early 2013[21] |
| China | Controlled substance | Effective 1 October 2015[21] |
| Finland | Controlled substance | Listed in government decree on narcotic substances[21] |
| Australia | Controlled substance | Listed by Office of Drug Control; specific schedule not confirmed[12] |
| Canada | Unknown | No specific scheduling information found as of 2026 |
| International | WHO ECDD Schedule II recommendation (1971 Convention) | Recommended for Schedule II placement[4] |
Legal status changes frequently and varies by jurisdiction. This information reflects available data as of 2026 and is not legal advice. Verify current status in any jurisdiction before making legal or safety decisions.
references
- [1]
- [2] ^abBunaim MK, Damanhuri HA, Yow HY, Yaakob NS, Makmor-Bakry M, Azmi N (2024) Understanding methiopropamine, a new psychoactive substance: an in-depth review on its chemistry, pharmacology and implications to human health — International Journal of Legal Medicine doi:10.1007/s00414-024-03201-7
- [3]
- [4]
- [5]
- [6] ^abcdFoti F, Marti M, Ossato A, Bilel S, Sangiorgi E, Botré F, Cerbelli B, Baldi A, De-Giorgio F (2019) Phenotypic effects of chronic and acute use of methiopropamine in a mouse model — International Journal of Legal Medicine doi:10.1007/s00414-018-1891-8